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time of infection clearance of HPV is usually short, even if the consensus
among researchers is lacking about this issue (Giuliano et al., 2011).
Giuliano reported that the mean time-to infection clearance (i.e., the
time necessary to determine a complete regression in at least 50% of
infected subjects) has been estimated to be 5.9 months, while the
complete clearance of HPV-DNA in at least 75% of infected subjects
has been estimated to occur within 12 months, independently of theUsing a clinical trial, Foresta and co-workers showed that the use
of prophylactic vaccination against human papillomaviruses (HPV)
in patients with HPV semen infection is effective in reducing virus
clearance time (Foresta et al., 2015). By using randomized controlled
trial, they demonstrated in 179 infertile patients from a cohort of 619
that HPV prophylactic vaccination is able to reduce the multiple infec-
tions and decrease prevalence of HPV semen infection at 12 months
(Foresta et al., 2015). On the basis of these ﬁndings, they suggested
that all patients attending assisted reproduction techniques centers
with HPV semen infection may beneﬁt by the union of both speciﬁc
counseling and available prophylactic vaccination. The results of this
trial highlight two important aspects to discuss: 1) the high prevalence
of HPV infection in males and the impact of HPV on semen quality and
2) the role ofmale prophylactic vaccination against HPV. The prevalence
of HPV in males ranges from 1.3 to 72.9%, but the majority of studies
conducted so far have been performed on speciﬁc male populations,
such as homosexuals or HIV-infected (Repp et al., 2012). Recently,
Bartoletti and coworkers reported a 27% prevalence of HPV in asymp-
tomatic men, highlighting that the HPV infection is often asymptomatic
and it allows a greater infection diffusion (Bartoletti et al., 2014). On the
other hand, a growing number of clinical trials reported a higher preva-
lence of HPV infection in semen from infertile patients (Garolla et al.,
2013; Cai et al., 2014). In this sense the HPV infection represents an
emergent problem for the management of couples eligible for assisted
reproduction techniques, too (Foresta et al., 2015). In other words,
men not only play a key role in the transmission of HPV to women,
but they are, probably, one of the targets of HPV viruses. Therefore, little
is known about the natural history of HPV infections in men. Extensive
knowledge of the natural history of HPV is an absolute requirement
when prevention strategies, such as vaccination programs, are designed
and implemented. For that reason, this is the time to re-think the role ofom.2015.09.005.
. This is an open access article underHPV genotype considered (Giuliano et al., 2011). These ﬁndings,
however, should be viewed in the light of the biological samples collected
from patients. On the one hand, Giuliano and co-workers evaluated the
HPV-DNA presence by using swabs obtained from the coronal sulcus,
glans penis, penile shaft, and scrotum (Giuliano et al., 2011). Moreover,
they did not evaluate the HPV-DNA on the semen. On the other hand,
Foresta evaluated theHPVDNAon the semen samples. Semen represents
a sampling site of high diagnostic value not only for the assessment of
HPV infection in asymptomatic males (Laprise et al., 2014), but also for
the evaluation of the mean time-to infection clearance. Moreover,
semen sample analysis for HPV in males shows sufﬁciently accurate
due to higher compliance of patients to sampling procedure, as reported
by Kyo et al. (Kyo et al., 1994). Finally, the role of male prophylactic
vaccination against HPV in themanagement and control of HPV infection
diffusion. The main disparity in vaccination rate between males and
female is due to the lack of data in the assessment of cost-effectiveness
of HPV vaccine use in males (Cifu and Davis, 2014). Vaccination in
males could reduce both the prevalence of cervical cancers and the evi-
dence of HPV-related cancers/genital warts. This aspect has been demon-
strated by several randomized control trials with the quadrivalent HPV
vaccine that demonstrate robust antibody responses and high efﬁcacy
against genital warts anal precancers in men (Stanley, 2014). However
gender-neutral vaccination has been recommended in the USA, Canada,
Austria, and Australia. Careful cost effective modeling has preceded
these decisions showing that when the burden of disease in men is in-
cluded in the models then, depending upon coverage, vaccine price,
and other factors male vaccination can become cost effective (Stanley,
2014). Even if the cost-effective analysis is essential in order to diffuse
the vaccination in males, the Foresta's study increases our knowledge
in the direction of male vaccination programworldwide approval. As fu-
ture developments we must consider: 1) evaluating the best biological
sample to use in order to evaluate the mean time-to infection clearance
in males, 2) evaluating the role of prophylactic vaccination against HPV
in males to maintain healthy male fertility. Finally, the key messages to
take into account are: 1) humoral immunity has a major role in healingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1301T. Cai / EBioMedicine 2 (2015) 1300–1301from HPV infection; 2) patients positive to HPV semen infection and eli-
gible for assisted reproduction techniques may beneﬁt by the union of
both speciﬁc counseling and available prophylactic vaccination.
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